Burden of Liver Cancer in China from 1990 to 2019 and projections to 2044:
 Findings from the Global Burden of Disease Study

Jianglong Han^a*, Chao Chen^b*, Tian Tang^a*, Wenmin Liu^a, Ruyan Chen^a, Si Li^a,
Haiyu Deng^a, Tingting Jian^a, Liang Zhao^{c#}, Zhenming Fu^{a#}

5 ^aCancer Center, Renmin Hospital of Wuhan University, Wuhan, 430060, China

- 6 ^bDepartment of Anorectal Surgery, the 8th Hospital of Wuhan, Wuhan, 430010, China
- ^cDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan,
 430060, China
- 9

10 Short title: Liver cancer burden in China

- 11
- 12 *These authors contributed equally to this paper.
- 13 #Correspondence to:
- 14 Dr. Zhenming Fu, Cancer Center, Renmin Hospital of Wuhan University, Wuhan,
- 15 430060, China. E-mail: <u>davidfuzming@whu.edu.cn</u>.
- 16 Dr. Liang Zhao, Department of Gastroenterology, Renmin Hospital of Wuhan
- 17 University, Wuhan, 430060, China. E-mail: <u>airmanzhao@whu.edu.cn</u>
- 18 Number of Tables: 2.
- 19 Number of Figures: 3.
- 20 Word count for main text: 2,861 words.
- 21 **Guarantor of the article**: ZF and LZ;
- 22 Specific author contributions: ZF, LZ, JH, TT and CC: conception/design. JH, CC,

TT, and WL: collection and/or assembly of data. JH, CC, TT, and RC: data analysis and interpretation. JH, CC, RC, SL, HD and TJ: manuscript writing. JH, CC, TT, WL,

25 RC, SL, HD, TJ, and ZF: final approval of manuscript. The work reported in the paper

- 26 has been performed by the authors, unless clearly specified in the text.
- Financial support: This study was partially supported by the National Natural Science Foundation of China [grants 81773555], the funders had no role in the design
- 29 of the study or the interpretation of the findings.
- 30 Potential competing interests: The authors declare that the research was conducted
- 31 in the absence of any commercial or financial relationships that could be construed as
- 32 a potential conflict of interest.

33 Abstract

Background: China has the highest liver cancer burden in the world. Prediction and
 comparison of the future trends of liver cancer in China and some representative areas
 may guide further control action.

Methods: Using data from the Global Burden of Disease Study, we assessed incidence, mortality, and disability-adjusted life-years of liver cancer in Mainland China, with reference to representative East Asia areas (Taiwan China, Japan, and Korea) and Western areas (the United Kingdom and the United States). The burden of liver cancer was evaluated and predicted using NOREPRED model from 1990 to 2044.

Results: Overall, the liver cancer incidence (28.1 to 10.6 per 100,000) and mortality 43 44 (27.5 to 9.7 per 100,000) decreased from 1990 to 2015 in Mainland China, which 45 were consistent with the trends of Eastern Asia areas. However, the disease burden in 46 Mainland China were then plateaued and started to increase during 2015-2044 (10.6 47 to 14.8 per 100,000 for incidence; 9.7 to 14.02 per 100,000 for mortality), including 48 the hepatitis-related liver cancer incidence (increase from 8.6 to 11.7 per 100,000). 49 While the changing patterns of alcohol- and nonalcoholic steatohepatitis (NASH)-50 related liver cancer incidence were found similar among Mainland China (0.93 to 1.51 51 per 100,000 for alcohol; 0.5 to 0.73 per 100,000 for NASH) and Western countries in 52 our projection.

53 Conclusion: The liver cancer burden in Mainland China is unexpectedly predicted to 54 increase again after decades of decline. Future efforts must be made to resolve both 55 the remaining hepatitis-related cancer burden and the changing etiologies.

56 Keyword: Liver cancer; Disease burden; Projection; Age-period-cohort analysis;
57 Global Burden of Disease Study.

58 Introduction

59 Liver cancer is the sixth most common malignancy and the third cause of cancer-60 related death worldwide, with approximately 905,677 new cases and 830,180 deaths 61 in 2020(1). The disease burden of liver cancer has increased globally over the last few 62 decades, with the highest disease burden observed in East Asia(2, 3), especially in Mainland China(1). In 2020, Mainland China had 410,038 newly diagnosed liver 63 64 cancer cases and 391,105 related deaths, which comprised half the global burden(1). 65 Fortunately, attributed to great public health efforts in controlling hepatitis virus infection, the incidence and mortality rates of liver cancer were reported to be 66 67 declining in East Asia in recent studies(4, 5).

68 Hepatitis B virus (HBV) and hepatitis C virus (HCV) infection are the main risk 69 factors for liver cancer development, accounting for almost half of the cases 70 worldwide(6). Currently, HBV infection is still the leading risk factor for liver cancer 71 in China, while HCV infection is the major risk factor for liver cancer in South Korea 72 and Japan and other developed areas(7, 8). However, liver cancer is a multifactorial 73 disease(9). Other modifiable factors such as obesity and unhealthy lifestyles, 74 including alcohol consumption, intake of fatty food, and lack of exercise, also play 75 important roles in its development(10). Recently, it is reported that the high 76 prevalence of alcoholic liver disease (ALD) and nonalcoholic fatty liver disease 77 (NAFLD) or nonalcoholic steatohepatitis (NASH) in Western populations result in the 78 upward trend in liver cancer (11, 12). The heterogeneous prevalence of risk factors in 79 different regions may also lead to different disease burdens. In the past few decades, 80 great efforts have been undertaken in East Asia, including Mainland China(13), to 81 prevent hepatitis virus infection through national vaccination programs, blood supply 82 management, and management of virus carriers. Therefore, the prevalence of hepatitis 83 infection and related liver cancer burden was found to decline in this area(14-16).

84 Recently, there has been significant increase in the consumption of alcohol, refined 85 grains, and highly processed foods, while physical activity decreased with increasing sedentary behaviors in Mainland China(17). As a result, the rapid emergence of 86 87 alcohol- and NASH-related liver cancer may offset or even surpass the likely decline 88 in the burden of hepatitis-related liver cancer in Mainland China. Therefore, we used 89 the data derived from the Global Burden of Disease (GBD) Study 2019 to examine 90 the current trends of liver cancer burden in China by specific etiologies and projected 91 the trends to 2044.

92

93 Materials and methods

94 **Data source**

95 The GBD study provides a standardized approach for estimating incidence, mortality,

96 and disability-adjusted life-years (DALYs), as well as DALYs by cause, age, sex, year, 97 and location, aiming to use all accessible information on disease occurrence, natural 98 history, and severity that passes a set of inclusion criteria(18). The detailed methods of 99 the GBD study (1990-2019) have been reported in previous studies(18, 19). We 100 collected annual liver cancer case data between 1990 and 2019 by sex, region 101 (Mainland China, East Asia areas: Taiwan China, Japan, and Republic of Korea; 102 Western areas: US and UK), etiology (alcohol use, HBV, HCV, and NASH), and age 103 group (from under 5 to 85+ years in 5-year intervals) from the Institute for Health 104 Metrics and Evaluation (http://ghdx.healthdata.org/gbd-results-tool). The data on incidence, mortality, and DALYS were chosen as measures in the inquiry tools. The 105 106 age-standardized incidence (ASIR), mortality (ASMR), and DALY (ASDR) rates 107 were adjusted by the World Health Organization standard population distribution 108 (2000-2025) per 100,000 person-years. Patient consent was not required because the study is a retrospective database research in nature, and there was no direct patient 109 110 contact. Institutional Review Board approval was not required according to our 111 institution policy.

112 Statistical analysis

We described the liver cancer incidence, mortality, and DALYs by 5-year age groups, locations, and etiologies. Temporal trends of these variables were plotted by location and etiology using the age-standardized rates. The temporal trends were divided into two periods: 1990-2019 was regarded as the observed trend plotted as solid lines, and 2020-2044 was regarded as the predicted trend plotted as dashed lines.

118 We used a log-linear age-period-cohort model to level off exponential growth and limit linear trend forecasts to observed trends (1990-2019). The NOREPRED package 119 120 with Power5 and Poisson APC models in R software were developed and 121 implemented in projecting trends into the future(20). We further utilized the APC 122 method to make projections of liver cancer burden up to 2044. Projections were 123 carried out in 5-year intervals through 2020-2044. Changing trends in observed periods (1990-2019) were extrapolated using the power function of the NOREPRED 124 125 package to level off the growth, with a projection of the linear trends for the last two observed 5-year periods. The projected trend was attenuated by 25% and 50% for the 126 second (2025-2029) and third (2030-2034) predicted periods, respectively, and then 127 128 75% for the fourth and fifth projected periods (2035-2044)(21). The predicted 129 population by age group and region from 2020 to 2044 was obtained from the United 130 Nations World Population Prospects 2019 Revisions in a 5-year period(21). R 4.1 was 131 used for analysis, including the functions available in R studio and the NORDPRED 132 package. GraphPad Prism 8 was used to visualize the results.

133

134 **Results**

135 Incidence, mortality, and DALYs of liver cancer by region, 1990-2019

Overall, the highest incidence, mortality, and DALY rates of liver cancer were 136 observed in East Asia from 1990 to 2019 (Figure 1A, 2A, and 3A). The highest ASIR 137 was observed in Mainland China at 28.1 per 100,000 in 1990, followed by Japan at 138 16.16 per 100,000, Taiwan China, at 12.83 per 100,000, and South Korea at 9.14 per 139 140 100,000. Between 1990 and 2019, continuously decreased incidences were observed 141 in Mainland China, Japan, and Taiwan China, whereas the incidence in South Korea 142 increased 184% from 1990 to 2004 and then decreased from 23.63 to 11.44 per 100,000 through 2019. The UK (2.01 to 4.82 per 100,000) and US (2.36 to 4.94 per 143 144 100,000) showed slight but continuous increases in incidence over the period.

Similarly, the highest ASMR and ASDR were observed in Mainland China, followed by Japan, Taiwan China, and South Korea in 1990, but significant decreasing trends were also observed in these areas. The figures in Mainland China decreased for more than two decades from 1990 to 2015 but started to increase again in 2015. However, unlike the trends of ASIR and ASDR, the temporal trends of South Korea decreased in the ASMR through 2019. Slight but steady increases in ASMR and ASDR were observed in the UK and US.

152 Incidence, mortality, and DALYs of liver cancer by etiology, 1990-2019

153 Among all four underlying etiologies, the highest disease burden was observed in 154 HBV-related liver cancer, followed by HCV, alcohol consumption, and NASH in China and selected areas (Table 1). Overall, the highest ASIRs were observed in 155 156 Mainland China among HBV (18.63 per 100,000), alcohol (2.1 per 100,000), and NASH-related (1.06 per 100,000) liver cancer in 1990, whereas the highest HCV-157 related ASIR of liver cancer (10.45 per 100,000) was seen in Japan. Remarkable 158 159 decreases were found in the ASIRs of alcohol (-62%), HBV (-64%), HCV (-63%), 160 and NASH (-60%) related to liver cancer in Mainland China from 1990 to 2015, and ASIRs have plateaued or slightly increased since 2015 (Table 2). In contrast, the 161 162 ASIR of South Korea showed a rapid increase from 1990 to 2004 among all etiology-163 related liver cancers and then slowly decreased through 2019. Similar increasing 164 trends were observed in the US and UK for liver cancers due to alcohol and NASH, whereas the ASIRs of hepatitis virus-related liver cancer plateaued in the UK and US 165 throughout the study periods. Similar trends for ASMR and ASDR were also found in 166 167 all regions regardless of etiology, with the highest disease burden of hepatitis virus-168 related liver cancers in Eastern countries and consistent upward trends in alcohol and NASH-related disease in Western countries. 169

170 Prediction of incidence, mortality, and DALYs of liver cancer, 2020-2044

171 Based on GBD data on liver cancer from 1990 to 2019, we further predicted the ASIR,

- ASMR, and ASDR in the next 25 years (Figures 1, 2, 3). By region, Mainland China,
- the US, and the UK showed continuous increases in incidence, mortality, and DALYs.
- 174 The increases in Mainland China were 44% for incidence and 42% for mortality and
- 175 DALYs, while the increases in incidence, mortality, and DALYs were 12.4%, 2.4%, 176 and 6.6% for the UK and 2.6%, 3.2%, and 7.5% for the US, respectively (**Table 2**). In
- the rest of the regions, the incidence of liver cancer is predicted to decrease by 48.7%
- for Japan, 21.5% for Taiwan China, and 25.6% for Korea from 2020 to 2044, while
- 179 mortality and DALYs in these areas will decline in a similar manner.

180 Universal increasing trends were observed for Mainland China for all etiological 181 factors in incidence, mortality, and DALYs from 2020 to 2044. For HBV-related liver 182 cancers, which are the predominant hepatitis virus-related liver cancers in Mainland China, trends were predicted to continuously increase in incidence (from 6.86 to 9.43 183 per 100,000), mortality (6.03 to 8.59 per 100,000), and DALYs (188.89 to 272.49 per 184 100,000) from 2020 to 2044. In Western areas, the incidence of liver cancer due to 185 186 alcohol will increase by 6.7% for the UK and 16.1% for the US from 2020 to 2044, whereas NASH-related liver cancer increases by 15.1% for the UK and 10.6% for the 187 188 US. However, mortality and DALYs will plateau in the UK and US over the predicted

189 periods (Figure 2D, E and Figure 3D, E).

190 **Discussion**

191 In this study, we demonstrated the highest incidence of liver cancer was observed in Mainland China in 1990 at 28.1 per 100,000 and then declined considerably and 192 193 ended at 10.6 per 100,000 in 2015. Unexpectedly, for the first time, we found that the 194 liver cancer burden has started to increase again in Mainland China since 2015, unlike 195 the continuous decline in other East Asian areas. Moreover, we predicted that it will 196 continue to increase for the next 25 years and remain 14.8 per 100,000 in 2044, due to 197 the remaining hepatitis-related cancer burden and increase in alcohol-related and 198 NASH-related liver cancers. This alarming projection may imply immediate public 199 health action in China.

200 Consistent with previous studies(4, 5, 22), the incidence and mortality rates of liver 201 cancer in the current study decreased in East Asia in the past few decades. The decline 202 in liver cancer burden among East Asia areas were clearly attributed to the efforts in 203 preventing hepatitis virus infection. Japanese government launched national projects 204 for HCV blood test since 1989 and provided interferon therapy for HCV-positive 205 adults for five years since 2002(23). Consequently, the incidence of liver cancer in 206 Japan peaked in 2000-2004 and decreased thereafter(24). We also found the plateaued incidence of liver cancer between 2000-2004 in this study and decreased by 78% 207 208 between 2004 and 2044 in Japan (Figure 1A). Similarly, the government of Taiwan 209 China and South Korea launched universal HBV vaccination programs in 1984 and

1995, respectively(24). Subsequently, HBV-related liver cancer incidence in young 210 211 adults was reported to decrease significantly(25). Followed these East Asia areas, the 212 government of Mainland China has issued a "blood donation law" since 1998, which 213 regulated blood donation and prevented the blood transmission of HBV. Furthermore, 214 a nationwide policy of free HBV vaccination for all newborns and children has been 215 universally implemented since 2002(26, 27). These efforts markedly reduced the HBV surface antigen (HBsAg) carrier rates in Chinese populations from 10.22% to 3.59% 216 217 (unvaccinated vs. vaccinated population)(28, 29). Along with these effective public health policies, our results showed that the hepatitis-related liver cancer burden in 218 219 Mainland China sharply decreased from 23.1 per 100,000 (18.6 per 100,000 for HBV; 6.9 per 100,000 for HCV) in 1990 to 8.6 per 100,000 (6.9 per 100,000 for HBV; 1.7 220 221 per 100,000 for HCV) in 2015, following what had happened in Japan, Korea, and the 222 rest of East Asia (Table 1).

223 However, unlike the consistently declined liver cancer burden in other East Asia areas, 224 the hepatitis-related cancer burden in Mainland China remained stable between 2015-225 2019 and projected to increase till 2044 in our study (9.4 per 100,000 for HBV; 2.3 226 per 100,000 for HCV). As previously reported in South Korea and Taiwan China, the 227 "lag effect" might account for the elevated disease burden in Mainland China, where 228 the incidence of liver cancer among elderly hepatitis reservoirs remains high(15, 30). 229 Yue et al. found that the rate of elderly HCC patients increased by 55.9% in Mainland 230 China over 3 decades, related deaths increased by 39.9%, and the corresponding 231 disease burden increased by 31.4%(31). Moreover, less than one-third of Chinese 232 adults were reported to establish vaccine-mediated immunity for hepatitis virus, and 233 these high-risk people might eventually contribute to the elevated disease burden of 234 liver cancer in China(32). Taken together, it was necessary for the Chinese government to implement a nationwide catch-up vaccination policy in the adult 235 236 population. In addition, active treatment policies for hepatitis reservoirs should also 237 be enhanced, while approximately 28 million HBV carriers and 200,000 new HCV 238 cases need treatment in Mainland China(33, 34).

239 In addition to the remaining hepatitis-related cancer burden, emerging challenges such 240 as alcohol and NASH might be responsible for the rapid increasing liver cancer 241 burden in Mainland China. In the current study, increased liver cancer burden in the 242 UK and US was widely observed, where alcohol and NASH rather than hepatitis virus 243 played major roles in contrast to East Asia(12, 35). Interestingly, the changing 244 patterns of alcohol- and NASH-related liver cancer incidence were found similar 245 among Mainland China (0.93 to 1.51 per 100,000 for alcohol; 0.5 to 0.73 per 100,000 246 for NASH) and Western countries in our projection (Figure 1D, E), which indicated 247 the changing etiologies of liver cancer in Mainland China(36). Over decades, the 248 alcohol consumption almost doubled from 4.1 liters to 7.2 liters per person in 249 Mainland China, and 22.7% of Chinese adults had engaged in heavy episodic 250 drinking(37). Similarly, overweight and obesity have increased rapidly in the past four decades in China, with rates estimated at 11.1% for overweight and 7.9% for obesity in children and adolescents(17), total liver cancer cases were estimated to increase 48% from 2016 to 2030, considering the emerging NAFLD- and NASH-related cases(38). Consistent with the prevalence of alcohol abuse and overweight, we predicted that the incidence of alcohol- and NASH-related liver cancer increase by 62% and 46%, respectively, in Mainland China during 2020-2044.

257 Therefore, it is vital to prevent alcohol abuse and obesity from individual and 258 government aspects. For individuals, interventions should be provided by trained staff 259 to initiate changes in risky binge drinking once individuals are screened or assessed 260 for problematic alcohol use(39). In addition, increasing alcohol taxes, the alcohol 261 policy environment, including liquor licensing laws, accessibility restrictions, and 262 minimum legal drinking age laws, should be enhanced by the government to reduce 263 alcohol use at the population level(40). Healthy diet, increased physical activity, and 264 weight loss should be encouraged for overweight individuals(41). Of importance, universal education for obesity control must be provided to better inform the public in 265 266 Mainland China(42), in particular, promoting changes in lifestyle and diet for Chinese 267 children to help relieve the future obesity burden(43).

268 Our study is population-based and incorporates high-quality data from the GBD study, which reliably collects and classifies cancer cases at the global level. Nevertheless, 269 270 several limitations should be noted. First, some important etiologies, such as aflatoxin 271 B1, tobacco smoking, and multi-etiological liver cancer, were not discussed due to the 272 scarcity of data in the GBD database. Second, the NOREPRED model performs 273 projection based on the assumption that trends observed in the past will continue in 274 the future, which may not be the case. In addition, data from the GBD database may 275 not be detailed enough to make precise predictions. For example, we recently found 276 an overall decline in the disease burden of hepatocellular carcinoma in the US 277 population using the SEER database, in contrast to the currently increasing trends(44); 278 besides, An et al. observed the overall decline in HCC incidence among Chinese 279 population from national database(16), thus, our findings must be interpreted with 280 caution. Third, GBD studies provide metrics rather than original data; however, the 281 GBD database is an unparalleled resource for the overall prediction and comparison 282 of disease trends among countries and regions. Although the prediction should be 283 reexamined comprehensively using more detailed and original data from the national 284 registry of China, the possible resurgence of liver cancer burden found in our study is 285 alarming. Previous studies have predicted that the disease burden will continue to 286 decline in Mainland China(45). Our timely prediction is important in urging the 287 Chinese society to rethink and take action to prevent the emerging resurgence of the 288 liver cancer burden.

289

290 Conclusion

291 Unexpectedly, the current study predicted that the declined liver cancer burden in 292 Mainland China will reverse and increase again through 2044, due to remaining 293 hepatitis-related cancer burden and changing prevalence of alcohol and NASH in 294 Mainland China. The increasing trend we predict requires vigilance from the public 295 health care providers and policymakers in China and calls for enhanced prevention and treatment of hepatitis reservoirs. Besides, we specifically propose the 296 297 encouragement of enhanced lifestyle modifications, such as drinking cessation and 298 obesity prevention, especially for the younger generation in Mainland China. Our 299 analyses are informative and may guide further action for control the liver cancer 300 burden in Mainland China.

301

Abbreviations: ASDR: age-standardized disability-adjusted life-years rate; ALD:
alcoholic liver disease; ASIR: age-standardized incidence rate; ASMR: agestandardized mortality rate; DAA: Direct-acting antiviral; DALYS: disability-adjusted
life-years; GBD: the Global Burden of Disease study; HBV: Hepatitis B virus; HBsAg:
Hepatitis B virus surface antigen; HCV: Hepatitis C virus; NAFLD: nonalcoholic
fatty liver disease; NASH: nonalcoholic steatohepatitis; UK: the United Kingdom; US:
the United States of America.

309

310 Acknowledgement

311 We sincerely thank the work performed by the Global Burden of Disease Study 2019 312 collaborators for providing this invaluable database.

313

314 Ethical approval statement

Ethical approval and consent were not required as this study was based on publiclyavailable data.

317

318 Patient consent

319 Patient consents were not required in accordance with local institution guidelines 320 because the study is a retrospective database research in nature, there was no direct 321 patient contact. Institutional Review Board approval was not required according to 322 our institution policy.

323

324 Author contribution

325 ZF and LZ: guarantor of the article. ZF, LZ, JH, TT and CC: conception/design. JH,

- 326 CC, TT, and WL: collection and/or assembly of data. JH, CC, TT, and RC: data
- 327 analysis and interpretation. JH, CC, RC, SL, HD and TJ: manuscript writing. JH, CC,
- 328 TT, WL, RC, SL, HD, TJ, and ZF: final approval of manuscript. The work reported in
- 329 the paper has been performed by the authors, unless clearly specified in the text.
- 330

331 Declaration of interest

- 332 The authors declare that the research was conducted in the absence of any commercial
- 333 or financial relationships that could be construed as a potential conflict of interest.
- 334

335 Funding information

- This study was partially supported by the National Natural Science Foundation of China [grants 81773555], the funders had no role in the design of the study or the interpretation of the findings.
- 339

340 Data sharing statement

341 The datasets generated for this study are available on request to the corresponding342 author (Davidfuzming@whu.edu.cn).

343 **References**

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.
 Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality
 Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021;71:209 249;10.3322/caac.21660.

Xia C, Dong X, Li H, Cao M, Sun D, He S, Yang F, Yan X, Zhang S, Li N, Chen
W. Cancer statistics in China and United States, 2022: profiles, trends, and
determinants. Chin Med J (Engl) 2022;135:584590;10.1097/CM9.00000000002108.

Global Burden of Disease Cancer Collaboration. Global, Regional, and National
 Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and
 Disability-Adjusted Life-years for 32 Cancer Groups, 1990 to 2015: A Systematic
 Analysis for the Global Burden of Disease Study. JAMA Oncol 2017;3:524 548;10.1001/jamaoncol.2016.5688.

4. Bai L, Liu Z, Fang Q, Yan Q, Shi O, Bao P, Mu L, Chen X, Zhang T. The trends
and projections in the incidence and mortality of liver cancer in urban Shanghai: a
population-based study from 1973 to 2020. Clin Epidemiol 2018;10:277288;10.2147/CLEP.S153951.

5. Wu J, Yang S, Xu K, Ding C, Zhou Y, Fu X, Li Y, Deng M, Wang C, Liu X, Li L.
Patterns and Trends of Liver Cancer Incidence Rates in Eastern and Southeastern
Asian Countries (1983-2007) and Predictions to 2030. Gastroenterology
2018;154:1719-1728 e1715;10.1053/j.gastro.2018.01.033.

365 6. Global Burden of Disease Liver Cancer Collaboration. The Burden of Primary
366 Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional,
367 and National Level: Results From the Global Burden of Disease Study 2015. JAMA
368 Oncol 2017;3:1683-1691;10.1001/jamaoncol.2017.3055.

Fan JH, Wang JB, Jiang Y, Xiang W, Liang H, Wei WQ, Qiao YL, Boffetta P.
Attributable causes of liver cancer mortality and incidence in china. Asian Pac J **Cancer Prev** 2013;14:7251-7256;10.7314/apjcp.2013.14.12.7251.

372 8. McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of Hepatocellular
373 Carcinoma. Hepatology 2021;73 Suppl 1:4-13;10.1002/hep.31288.

374 9. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S,
375 Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev
376 Dis Primers 2021;7:6;10.1038/s41572-020-00240-3.

10. Anstee QM, Reeves HL, Kotsiliti E, Govaere O, Heikenwalder M. From NASH

to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol
2019;16:411-428;10.1038/s41575-019-0145-7.

- 11. Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM.
 Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort
 study. BMJ 2011;343:d6891;10.1136/bmj.d6891.
- 12. Dang K, Hirode G, Singal AK, Sundaram V, Wong RJ. Alcoholic Liver Disease
 Epidemiology in the United States: A Retrospective Analysis of 3 US Databases. Am
 J Gastroenterol 2020;115:96-104;10.14309/ajg.00000000000380.
- 13. Liu Z, Mao X, Jiang Y, Cai N, Jin L, Zhang T, Chen X. Changing trends in the
 disease burden of primary liver cancer caused by specific etiologies in China. Cancer
 Med 2019;8:5787-5799;10.1002/cam4.2477.
- 14. Tanaka H, Imai Y, Hiramatsu N, Ito Y, Imanaka K, Oshita M, Hijioka T,
 Katayama K, Yabuuchi I, Yoshihara H, Inoue A, Kato M, Takehara T, Tamura S,
 Kasahara A, Hayashi N, Tsukuma H. Declining incidence of hepatocellular carcinoma
 in Osaka, Japan, from 1990 to 2003. Ann Intern Med 2008;148:820826;10.7326/0003-4819-148-11-200806030-00004.
- 394 15. Ni YH, Chen DS. Hepatitis B vaccination in children: the Taiwan experience.
 395 Pathol Biol (Paris) 2010;58:296-300;10.1016/j.patbio.2009.11.002.
- 16. An L, Zheng R, Zhang S, Chen R, Wang S, Sun K, Lu L, Zhang X, Zhao H, Zeng
 H, Wei W, He J. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma
 incidence between 2006 and 2015 in China: estimates based on data from 188
 population-based cancer registries. Hepatobiliary Surg Nutr 2023;12:4555;10.21037/hbsn-21-75.
- 401 17. Pan XF, Wang L, Pan A. Epidemiology and determinants of obesity in China.
 402 Lancet Diabetes Endocrinol 2021;9:373-392;10.1016/S2213-8587(21)00045-0.
- 403 18. G. B. D. Disease Injury Incidence Prevalence Collaborators. Global, regional, and
 404 national incidence, prevalence, and years lived with disability for 354 diseases and
 405 injuries for 195 countries and territories, 1990-2017: a systematic analysis for the
 406 Global Burden of Disease Study 2017. Lancet 2018;392:1789-1858;10.1016/S0140407 6736(18)32279-7.
- 408 19. G. B. D. Diseases Injuries Collaborators. Global burden of 369 diseases and
 409 injuries in 204 countries and territories, 1990-2019: a systematic analysis for the
 410 Global Burden of Disease Study 2019. Lancet 2020;396:1204-1222;10.1016/S0140411 6736(20)30925-9.
- 20. Moller B, Fekjaer H, Hakulinen T, Sigvaldason H, Storm HH, Talback M,
 Haldorsen T. Prediction of cancer incidence in the Nordic countries: empirical
 comparison of different approaches. Stat Med 2003;22:2751-2766;10.1002/sim.1481.
- 415 21. Araghi M, Soerjomataram I, Jenkins M, Brierley J, Morris E, Bray F, Arnold M.
 416 Global trends in colorectal cancer mortality: projections to the year 2035.

417 International Journal of Cancer 2019;144:2992-3000;10.1002/ijc.32055.

418 22. Katanoda K, Ito Y, Sobue T. International comparison of trends in cancer
419 mortality: Japan has fallen behind in screening-related cancers. Jpn J Clin Oncol
420 2021;51:1680-1686;10.1093/jjco/hyab139.

421 23. Yu ML, Chuang WL. Treatment of chronic hepatitis C in Asia: when East meets
422 West. J Gastroenterol Hepatol 2009;24:336-345;10.1111/j.1440-1746.2009.05789.x.

423 24. Tsukuma H, Tanaka H, Ajiki W, Oshima A. Liver cancer and its prevention.
424 Asian Pac J Cancer Prev 2005;6:244-250

25. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, Liang DC, Shau WY,
Chen DS. Universal hepatitis B vaccination in Taiwan and the incidence of
hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N
Engl J Med 1997;336:1855-1859;10.1056/NEJM199706263362602.

429 26. Jia Y, Li L, Cui F, Zhang D, Zhang G, Wang F, Gong X, Zheng H, Wu Z, Miao N,
430 Sun X, Zhang L, Lv J, Yang F. Cost-effectiveness analysis of a hepatitis B vaccination
431 catch-up program among children in Shandong Province, China. Hum Vaccin

432 **Immunother** 2014;10:2983-2991;10.4161/hv.29944.

27. Zhang Q, Qi W, Wang X, Zhang Y, Xu Y, Qin S, Zhao P, Guo H, Jiao J, Zhou C,
Ji S, Wang J. Epidemiology of Hepatitis B and Hepatitis C Infections and Benefits of
Programs for Hepatitis Prevention in Northeastern China: A Cross-Sectional Study.
Clin Infect Dis 2016;62:305-312;10.1093/cid/civ859.

437 28. Luo Z, Li L, Ruan B. Impact of the implementation of a vaccination strategy on
438 hepatitis B virus infections in China over a 20-year period. Int J Infect Dis
439 2012;16:e82-88;10.1016/j.ijid.2011.10.009.

440 29. Huang P, Zhu LG, Zhu YF, Yue M, Su J, Zhu FC, Yang HT, Zhang Y, Shen HB,
441 Yu RB, Zhai XJ, Peng ZH. Seroepidemiology of hepatitis B virus infection and
442 impact of vaccination. World J Gastroenterol 2015;21:7842443 7850;10.3748/wjg.v21.i25.7842.

444 30. Kim BH, Park JW. Epidemiology of liver cancer in South Korea. Clin Mol
445 Hepatol 2018;24:1-9;10.3350/cmh.2017.0112.

31. Yue T, Xu M, Cai T, Zhu H, Pourkarim MR, De Clercq E, Li G. Gender disparity
and temporal trend of liver cancer in China from 1990 to 2019 and predictions in a
25-year period. Front Public Health 2022;10:956712;10.3389/fpubh.2022.956712.

32. Bai X, Chen L, Liu X, Tong Y, Wang L, Zhou M, Li Y, Hu G. Adult Hepatitis B
Virus Vaccination Coverage in China from 2011 to 2021: A Systematic Review.
Vaccines (Basel) 2022;10;10.3390/vaccines10060900.

452 33. Xia R, Peng J, He J, Jiang P, Yuan C, Liu X, Yao Y. The Serious Challenge of

- 453 Occult Hepatitis B Virus Infection-Related Hepatocellular Carcinoma in China. Front
 454 Microbiol 2022;13:840825;10.3389/fmicb.2022.840825.
- 455 34. Mei X, Lu H. Prevalence, diagnosis, and treatment of hepatitis C in Mainland
 456 China. Glob Health Med 2021;3:270-275;10.35772/ghm.2021.01080.
- 35. Brown KF, Rumgay H, Dunlop C, Ryan M, Quartly F, Cox A, Deas A, EllissBrookes L, Gavin A, Hounsome L, Huws D, Ormiston-Smith N, Shelton J, White C,
 Parkin DM. The fraction of cancer attributable to modifiable risk factors in England,
 Wales, Scotland, Northern Ireland, and the United Kingdom in 2015. Br J Cancer
 2018;118:1130-1141;10.1038/s41416-018-0029-6.
- 36. Im PK, Millwood IY, Kartsonaki C, Guo Y, Chen Y, Turnbull I, Yu C, Du H, Pei P,
 Lv J, Walters RG, Li L, Yang L, Chen Z, China Kadoorie Biobank collaborative g.
 Alcohol drinking and risks of liver cancer and non-neoplastic chronic liver diseases in
 China: a 10-year prospective study of 0.5 million adults. BMC Med
 2021;19:216;10.1186/s12916-021-02079-1.
- 467 37. Hu A, Jiang H, Dowling R, Guo L, Zhao X, Hao W, Xiang X. The transition of
 468 alcohol control in China 1990-2019: Impacts and recommendations. Int J Drug
 469 Policy 2022;105:103698;10.1016/j.drugpo.2022.103698.
- 38. Estes C, Anstee QM, Arias-Loste MT, Bantel H, Bellentani S, Caballeria J,
 Colombo M, Craxi A, Crespo J, Day CP, Eguchi Y, Geier A, Kondili LA, Kroy DC,
 Lazarus JV, Loomba R, Manns MP, Marchesini G, Nakajima A, Negro F, Petta S,
 Ratziu V, Romero-Gomez M, Sanyal A, Schattenberg JM, Tacke F, Tanaka J,
 Trautwein C, Wei L, Zeuzem S, Razavi H. Modeling NAFLD disease burden in China,
 France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the
 period 2016-2030. J Hepatol 2018;69:896-904;10.1016/j.jhep.2018.05.036.
- 477 39. Kuntsche E, Kuntsche S, Thrul J, Gmel G. Binge drinking: Health impact,
 478 prevalence, correlates and interventions. Psychol Health 2017;32:976479 1017;10.1080/08870446.2017.1325889.
- 480 40. Balodis IM, Potenza MN, Olmstead MC. Binge drinking in undergraduates:
 481 relationships with sex, drinking behaviors, impulsivity, and the perceived effects of
 482 alcohol. Behav Pharmacol 2009;20:518-526;10.1097/FBP.0b013e328330c779.
- 483 41. Fan JG, Wei L, Zhuang H, National Workshop on Fatty L, Alcoholic Liver
 484 Disease CSoHCMA, Fatty Liver Disease Expert Committee CMDA. Guidelines of
 485 prevention and treatment of nonalcoholic fatty liver disease (2018, China). J Dig Dis
 486 2019;20:163-173;10.1111/1751-2980.12685.
- 487 42. The Lancet Diabetes Endocrinology. Obesity in China: time to act. Lancet
 488 Diabetes Endocrinol 2021;9:407;10.1016/S2213-8587(21)00150-9.
- 489 43. Chen J, Jin L, Wang F, Huang K, Wu W, Chen R, Maimaiti M, Chen S, Cao B,

Zhu M, Wang C, Su Z, Liang Y, Yao H, Wei H, Zheng R, Du H, Luo F, Li P, Yu Y,
Wang E, Dorazio RM, Fu J. Risk factors for obesity and overweight in Chinese
children: a nationwide survey. **Obesity (Silver Spring)** 2022;30:18421850;10.1002/oby.23515.

494 44. Han J, Wang B, Liu W, Wang S, Chen R, Chen M, Fu Z. Declining disease
495 burden of HCC in the United States, 1992-2017: A population-based analysis.
496 Hepatology 2022;76:576-588;10.1002/hep.32355.

- 497 45. Yue T, Zhang Q, Cai T, Xu M, Zhu H, Pourkarim MR, De Clercq E, Li G. Trends
- 498 in the disease burden of HBV and HCV infection in China from 1990-2019. Int J
- 499 **Infect Dis** 2022;122:476-485;10.1016/j.ijid.2022.06.017.

500

Period	Mainland China		Taiwan China			Japan			Republic of Korea			United Kingdom			United States of America			
Period	ASIR	ASMR	ASDR	ASIR	ASMR	ASDR	ASIR	ASMR	ASDR	ASIR	ASMR	ASDR	ASIR	ASMR	ASDR	ASIR	ASMR	ASDR
All causes																		
1990-1994	28.1	27.49	845.3	12.83	12.65	373.88	16.16	12.22	312.74	9.14	9.24	263.76	2.01	1.81	44.38	2.36	2.06	54.23
1995-1999	27.63	27.63	839.76	15.81	12.21	347.64	18.94	15.25	370.6	14.34	12.28	349.67	2.26	1.98	48.34	2.93	2.47	65.04
2000-2004	19.07	17.17	507.85	19.26	12.72	343.03	23.63	14.07	324.66	25.99	23.75	669.45	2.8	2.35	56.44	3.51	2.89	76.32
2005-2009	10.23	9.89	284.41	17.1	13.25	345.99	16.29	11.71	258.2	26.05	20.31	552.93	3.56	2.91	69.25	4.1	3.36	88.85
2010-2014	9.93	8.87	252.97	9.04	7.23	181.28	13.53	9.35	198.1	23.74	17.49	456.51	4.37	3.48	80.63	4.58	3.69	96.32
2015-2019	10.64	9.65	276.52	8.07	6.72	168.4	11.44	7.88	162.55	22.2	15.71	400.04	4.82	3.74	86.45	4.94	4.01	103.95
2020-2024	11.54	10.6	308.92	7.11	6.15	155.24	9.45	6.66	136.28	20.4	13.82	345.28	5.27	3.98	91.81	5.23	4.27	109.21
2025-2029	12.43	11.53	338.64	6.53	5.8	146.62	7.7	5.66	117.6	18.92	12.44	305.04	5.52	4.08	94.67	5.36	4.4	111.16
2030-2034	13.32	12.47	365.61	5.98	5.37	138.49	6.34	5.01	106.45	17.38	11.14	273.04	5.6	4.07	95.23	5.34	4.39	109.91
2035-2039	13.98	13.16	384.04	5.73	5.15	133.94	5.56	4.87	103.92	16.2	10.29	252.61	5.5	3.94	93.47	5.21	4.27	106.51
2040-2044	14.78	14.02	404.56	5.58	5.01	131.87	4.84	4.69	102.15	15.18	9.53	235.3	5.42	3.83	92.15	5.07	4.14	103.55
Alcohol																		
1990-1994	2.1	2.08	58.98	1.26	1.28	34.96	2.04	1.54	40.89	1.19	1.23	32.14	0.73	0.65	16.02	0.7	0.61	15.81
1995-1999	2.04	2.06	57.2	1.6	1.24	33.52	2.3	1.84	46.8	1.9	1.65	43.46	0.84	0.72	17.82	0.86	0.72	19.02
2000-2004	1.41	1.3	34.95	1.95	1.3	33.78	2.23	1.65	40.34	3.59	3.33	86.83	1.07	0.88	21.36	1.02	0.82	22.21
2005-2009	0.79	0.78	20.31	1.67	1.3	33.03	1.93	1.36	31.94	3.73	2.99	75.18	1.36	1.09	26.2	1.2	0.96	26
2010-2014	0.8	0.73	18.87	0.81	0.66	16.18	1.61	1.07	24.58	3.54	2.68	64.93	1.65	1.27	29.97	1.35	1.06	28.49
2015-2019	0.93	0.62	22.25	0.72	0.6	14.78	1.31	0.87	19.73	3.48	2.52	60.07	1.79	1.35	31.67	1.55	1.23	32.46
2020-2024	1.08	0.55	26.34	0.63	0.55	13.45	1.1	0.72	16.16	3.37	2.33	54.85	1.93	1.42	33.14	1.74	1.39	35.89

Table 1. Disease burden of liver cance	er from GBD	by etiologies,	1990-2044
--	-------------	----------------	-----------

			-		—			•			_	_					
1.21	0.5	30.18	0.57	0.52	12.71	0.94	0.61	13.77	3.25	2.18	50.58	2	1.44	33.71	1.85	1.48	37.73
1.33	0.5	33.61	0.53	0.5	12.24	0.84	0.55	12.4	3.07	1.99	46.54	2.01	1.42	33.52	1.88	1.5	37.92
1.41	0.51	35.88	0.52	0.49	12.15	0.8	0.53	12.05	2.9	1.86	43.54	1.95	1.37	32.62	1.84	1.46	36.87
1.51	0.53	38.54	0.51	0.48	12.36	0.77	0.53	11.92	2.75	1.74	41.04	1.91	1.33	31.87	1.8	1.43	36.05
18.63	17.81	588.81	7.01	6.72	219.66	2.51	1.82	56.18	5.77	5.68	177.81	0.32	0.26	7.86	0.35	0.29	8.92
18.45	18.08	588.06	7.89	5.93	190.56	2.31	2.13	62.64	9.08	7.56	235.63	0.35	0.28	8.52	0.43	0.34	10.56
12.75	11.19	355.65	8.94	5.61	174.67	2.62	1.85	52.56	16.52	14.72	451.23	0.43	0.33	9.82	0.52	0.4	12.31
6.71	6.32	197	7.7	5.68	172.9	2.25	1.49	41.05	16.41	12.36	367.12	0.55	0.41	12.12	0.6	0.45	13.86
6.49	5.65	174.89	3.92	2.97	87.75	1.86	1.17	31.22	14.53	10.35	297.62	0.68	0.48	14.02	0.64	0.48	14.36
6.86	6.03	188.89	3.65	2.89	85.05	1.49	0.94	24.67	13.18	9.01	254.84	0.75	0.52	15.23	0.69	0.52	15.54
7.43	6.59	210.38	3.36	2.79	82.25	1.16	0.75	19.72	11.83	7.71	215.08	0.83	0.55	16.38	0.73	0.55	16.31
7.98	7.13	230.09	3.2	2.75	80.43	0.94	0.62	16.46	10.74	6.77	186.44	0.89	0.57	17.18	0.75	0.56	16.71
8.54	7.69	247.7	3.05	2.67	78.43	0.79	0.53	14.52	9.79	5.99	165.46	0.92	0.58	17.6	0.75	0.56	16.68
8.95	8.1	259.64	2.98	2.63	77.12	0.71	0.51	13.8	9.11	5.5	152.65	0.92	0.56	17.61	0.73	0.54	16.34
9.43	8.59	272.49	2.96	2.63	77.2	0.65	0.48	13.23	8.54	5.08	142.13	0.93	0.55	17.68	0.72	0.53	16.1
4.51	4.78	109.09	3.24	3.39	81.09	10.45	8	192.61	1.41	1.55	33.18	0.69	0.67	14.06	0.83	0.76	17.9
4.34	4.68	105.88	4.56	3.7	85.05	12.48	10.19	233.55	2.19	2.03	43.51	0.77	0.73	15.08	1.05	0.94	22.06
2.98	2.93	64.44	6.12	4.33	94.17	12.46	9.54	207.07	3.82	3.76	82.19	0.94	0.85	17.34	1.27	1.1	26.23
1.68	1.77	37.54	5.67	4.69	98.55	10.9	8.02	165.34	3.85	3.3	69.61	1.19	1.06	21.35	1.5	1.3	31.06
1.6	1.56	32.49	3.1	2.67	53.11	9.02	6.41	126.34	3.72	2.98	59.56	1.49	1.3	25.54	1.71	1.44	34.56
1.7	1.71	35.54	2.66	2.37	46.77	7.77	5.49	105.17	3.63	2.81	53.96	1.65	1.4	27.68	1.77	1.51	35.81
	 1.21 1.33 1.41 1.51 18.63 18.45 12.75 6.71 6.49 6.86 7.43 7.98 8.54 8.95 9.43 4.51 4.34 2.98 1.68 1.6 1.7 	1.210.51.330.51.410.511.510.5318.6317.8118.4518.0812.7511.196.716.326.495.656.866.037.436.597.987.138.547.698.958.19.438.594.514.784.344.682.982.931.681.771.61.561.71.71	1.21 0.5 30.18 1.33 0.5 33.61 1.41 0.51 35.88 1.51 0.53 38.54 18.63 17.81 588.81 18.45 18.08 588.06 12.75 11.19 355.65 6.71 6.32 197 6.49 5.65 174.89 6.86 6.03 188.89 7.43 6.59 210.38 7.98 7.13 230.09 8.54 7.69 247.7 8.95 8.1 259.64 9.43 8.59 272.49 4.51 4.78 109.09 4.34 4.68 105.88 2.98 2.93 64.44 1.68 1.77 37.54 1.6 1.56 32.49 1.7 1.71 35.54	1.21 0.5 30.18 0.57 1.33 0.5 33.61 0.53 1.41 0.51 35.88 0.52 1.51 0.53 38.54 0.51 18.63 17.81 588.81 7.01 18.45 18.08 588.06 7.89 12.75 11.19 355.65 8.94 6.71 6.32 197 7.7 6.49 5.65 174.89 3.92 6.86 6.03 188.89 3.65 7.43 6.59 210.38 3.36 7.98 7.13 230.09 3.2 8.54 7.69 247.7 3.05 8.95 8.1 259.64 2.98 9.43 8.59 272.49 2.96 4.51 4.78 109.09 3.24 4.34 4.68 105.88 4.56 2.98 2.93 64.44 6.12 1.68 1.77 37.54 5.67 1.6 1.56 32.49 3.1	1.21 0.5 30.18 0.57 0.52 1.33 0.5 33.61 0.53 0.5 1.41 0.51 35.88 0.52 0.49 1.51 0.53 38.54 0.51 0.48 18.63 17.81 588.81 7.01 6.72 18.45 18.08 588.06 7.89 5.93 12.75 11.19 355.65 8.94 5.61 6.71 6.32 197 7.7 5.68 6.49 5.65 174.89 3.92 2.97 6.86 6.03 188.89 3.65 2.89 7.43 6.59 210.38 3.36 2.79 7.98 7.13 230.09 3.2 2.75 8.54 7.69 247.7 3.05 2.67 8.95 8.1 259.64 2.98 2.63 9.43 8.59 272.49 2.96 2.63 9.43 4.68 105.88 <t< td=""><td>1.21$0.5$$30.18$$0.57$$0.52$$12.71$$1.33$$0.5$$33.61$$0.53$$0.5$$12.24$$1.41$$0.51$$35.88$$0.52$$0.49$$12.15$$1.51$$0.53$$38.54$$0.51$$0.48$$12.36$$18.63$$17.81$$588.81$$7.01$$6.72$$219.66$$18.45$$18.08$$588.06$$7.89$$5.93$$190.56$$12.75$$11.19$$355.65$$8.94$$5.61$$174.67$$6.71$$6.32$$197$$7.7$$5.68$$172.9$$6.49$$5.65$$174.89$$3.92$$2.97$$87.75$$6.86$$6.03$$188.89$$3.65$$2.89$$85.05$$7.43$$6.59$$210.38$$3.36$$2.79$$82.25$$7.98$$7.13$$230.09$$3.2$$2.75$$80.43$$8.54$$7.69$$247.7$$3.05$$2.67$$78.43$$8.95$$8.1$$259.64$$2.98$$2.63$$77.12$$9.43$$8.59$$272.49$$2.96$$2.63$$77.2$$4.51$$4.78$$109.09$$3.24$$3.39$$81.09$$4.34$$4.68$$105.88$$4.56$$3.7$$85.05$$2.98$$2.93$$64.44$$6.12$$4.33$$94.17$$1.68$$1.77$$37.54$$5.67$$4.69$$98.55$$1.6$$1.56$$32.49$$3.11$$2.67$$53.11$</td><td>1.21 0.5 30.18 0.57 0.52 12.71 0.94 1.33 0.5 33.61 0.53 0.5 12.24 0.84 1.41 0.51 35.88 0.52 0.49 12.15 0.8 1.51 0.53 38.54 0.51 0.48 12.36 0.77 18.63 17.81 588.81 7.01 6.72 219.66 2.51 18.45 18.08 588.06 7.89 5.93 190.56 2.31 12.75 11.19 355.65 8.94 5.61 174.67 2.62 6.71 6.32 197 7.7 5.68 172.9 2.25 6.49 5.65 174.89 3.92 2.97 87.75 1.86 6.86 6.03 188.89 3.65 2.89 85.05 1.49 7.43 6.59 210.38 3.36 2.79 82.25 1.16 7.98 7.13 230.09 3.2 2.75 80.43 0.94 8.54 7.69 247.7 3.05</td><td>1.21$0.5$$30.18$$0.57$$0.52$$12.71$$0.94$$0.61$$1.33$$0.5$$33.61$$0.53$$0.5$$12.24$$0.84$$0.55$$1.41$$0.51$$35.88$$0.52$$0.49$$12.15$$0.8$$0.53$$1.51$$0.53$$38.54$$0.51$$0.48$$12.36$$0.77$$0.53$$1.51$$0.53$$38.54$$0.51$$0.48$$12.36$$0.77$$0.53$$18.63$$17.81$$588.81$$7.01$$6.72$$219.66$$2.51$$1.82$$18.45$$18.08$$588.06$$7.89$$5.93$$190.56$$2.31$$2.13$$12.75$$11.19$$355.65$$8.94$$5.61$$174.67$$2.62$$1.85$$6.71$$6.32$$197$$7.7$$5.68$$172.9$$2.25$$1.49$$6.49$$5.65$$174.89$$3.92$$2.97$$87.75$$1.86$$1.17$$6.86$$6.03$$188.89$$3.65$$2.89$$85.05$$1.49$$0.94$$7.43$$6.59$$210.38$$3.36$$2.79$$82.25$$1.16$$0.75$$7.98$$7.13$$230.09$$3.2$$2.75$$80.43$$0.94$$0.62$$8.54$$7.69$$247.7$$3.05$$2.63$$77.2$$0.65$$0.48$$4.51$$4.78$$109.09$$3.24$$3.39$$81.09$$10.45$$8$$4.34$$4.68$$105.88$$4.56$</td><td>1.21$0.5$$30.18$$0.57$$0.52$$12.71$$0.94$$0.61$$13.77$$1.33$$0.5$$33.61$$0.53$$0.5$$12.24$$0.84$$0.55$$12.4$$1.41$$0.51$$35.88$$0.52$$0.49$$12.15$$0.8$$0.53$$12.05$$1.51$$0.53$$38.54$$0.51$$0.48$$12.36$$0.77$$0.53$$11.92$$18.63$$17.81$$588.81$$7.01$$6.72$$219.66$$2.51$$1.82$$56.18$$18.45$$18.08$$588.06$$7.89$$5.93$$190.56$$2.31$$2.13$$62.64$$12.75$$11.19$$355.65$$8.94$$5.61$$174.67$$2.62$$1.85$$52.56$$6.71$$6.32$$197$$7.7$$5.68$$172.9$$2.25$$1.49$$41.05$$6.49$$5.65$$174.89$$3.92$$2.97$$87.75$$1.86$$1.17$$31.22$$6.86$$6.03$$188.89$$3.65$$2.89$$85.05$$1.49$$0.94$$24.67$$7.43$$6.59$$210.38$$3.36$$2.79$$82.25$$1.16$$0.75$$19.72$$7.98$$7.13$$230.09$$3.2$$2.75$$80.43$$0.94$$0.62$$16.46$$8.54$$7.69$$247.7$$3.05$$2.67$$78.43$$0.79$$0.53$$14.52$$8.95$$8.1$$259.64$$2.98$$2.63$$77.2$$0.65$$0.48$</td><td>1.21$0.5$$30.18$$0.57$$0.52$$12.71$$0.94$$0.61$$13.77$$3.25$$1.33$$0.5$$33.61$$0.53$$0.5$$12.24$$0.84$$0.55$$12.4$$3.07$$1.41$$0.51$$35.88$$0.52$$0.49$$12.15$$0.8$$0.53$$12.05$$2.9$$1.51$$0.53$$38.54$$0.51$$0.48$$12.36$$0.77$$0.53$$11.92$$2.75$$1.683$$17.81$$588.81$$7.01$$6.72$$219.66$$2.51$$1.82$$56.18$$5.77$$18.45$$18.08$$588.06$$7.89$$5.93$$190.56$$2.31$$2.13$$62.64$$9.08$$12.75$$11.19$$355.65$$8.94$$5.61$$174.67$$2.62$$1.85$$52.56$$16.52$$6.71$$6.32$$197$$7.7$$5.68$$172.9$$2.25$$1.49$$41.05$$16.41$$6.49$$5.65$$174.89$$3.92$$2.97$$87.75$$1.86$$1.17$$31.22$$14.53$$6.86$$6.03$$188.89$$3.65$$2.89$$85.05$$1.49$$0.94$$24.67$$13.18$$7.43$$6.59$$210.38$$3.36$$2.79$$82.25$$1.16$$0.75$$19.72$$11.83$$7.43$$6.59$$247.7$$3.05$$2.67$$78.43$$0.94$$0.62$$16.46$$10.74$$8.54$$7.69$$247.7$$3.05$$2.63$<</td><td>1.210.530.180.570.5212.710.940.6113.773.252.181.330.533.610.530.512.240.840.5512.43.071.991.410.5135.880.520.4912.150.80.5312.052.91.861.510.5338.540.510.4812.360.770.5311.922.751.741.86317.81588.817.016.72219.662.511.8256.185.775.6818.4518.08588.067.895.93190.562.312.1362.649.087.5612.7511.19355.658.945.61174.672.621.8552.5616.5214.726.716.321977.75.68172.92.251.4941.0516.4112.366.495.65174.893.922.9787.751.861.1731.2214.5310.356.866.03188.893.652.8985.051.490.9424.6713.189.017.436.59210.383.362.7982.251.160.7519.7211.837.717.987.13230.093.22.7580.430.940.6216.4610.746.778.547.69247.73.052.6377.20.650.4813.238.545.08</td><td>1.21 0.5 30.18 0.57 0.52 12.71 0.94 0.61 13.77 3.25 2.18 50.58 1.33 0.5 33.61 0.53 0.5 12.24 0.84 0.55 12.4 3.07 1.99 46.54 1.41 0.51 35.88 0.52 0.49 12.15 0.8 0.53 12.05 2.9 1.86 43.54 1.51 0.53 38.54 0.51 0.48 12.36 0.77 0.53 11.92 2.75 1.74 41.04 18.63 17.81 588.81 7.01 6.72 219.66 2.51 1.82 56.18 5.77 5.68 177.81 18.43 18.08 588.06 7.89 5.93 190.56 2.31 2.13 62.64 9.08 7.56 235.63 12.75 11.19 355.65 8.94 5.61 174.67 2.62 1.85 52.56 1.652 1.472 451.23 6.71 6.32 197 7.7 5.68 172.9 2.25 1.49 41.</td><td>1.210.530.180.570.5212.710.940.6113.773.252.1850.5821.330.533.610.530.512.240.840.5512.43.071.9946.542.011.410.5135.880.520.4912.150.80.5312.052.91.8643.541.951.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.86317.81S88.817.016.72219.662.511.8256.185.775.68177.810.321.84518.08S88.067.895.93190.562.312.1362.649.087.56235.630.351.27511.19355.658.945.61174.672.621.8552.5616.5214.72451.230.436.716.321977.75.68172.92.251.4941.0516.4112.36367.120.556.495.65174.893.922.9787.751.861.1731.2214.5310.35297.620.686.866.03188.893.652.8985.051.490.9424.6713.189.01254.840.757.436.59210.383.362.7982.251.160.7519.721.1837.71215.080.837.98</td><td>1.210.530.180.570.521.2.710.940.6113.773.252.1850.5821.441.330.533.610.530.512.240.840.5512.43.071.9946.542.011.421.410.5135.880.520.4912.150.80.5312.052.91.8643.541.951.371.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.331.841.781588.817.016.72219.662.511.8256.185.775.68177.810.320.2618.4518.08588.067.895.93190.562.312.1362.649.087.56235.630.350.2812.7511.19355.658.945.61174.672.621.8552.5616.5214.72451.230.430.336.716.321977.75.68172.92.251.4941.0516.4112.36367.120.550.416.495.65174.893.922.9787.751.861.1731.2214.3310.35297.620.680.486.866.03188.893.652.498.501.490.9424.6713.189.01254.840.750.527.436.5921.0383.362.47<t< td=""><td>1.210.530.180.570.5212.710.940.6113.775.252.1850.5821.4433.711.330.533.610.530.512.240.840.5512.43.071.9946.542.011.4233.521.410.5135.880.520.4912.150.80.5312.052.91.8643.541.951.3732.621.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.3331.871.6317.81588.817.016.72219.662.511.8256.185.775.68177.810.320.267.8618.4518.08588.067.895.93190.562.312.1362.649.087.56235.630.350.288.5212.7511.19355.658.945.61174.672.621.8552.5616.5214.72451.230.430.339.826.716.321977.75.68172.92.251.4941.0516.4112.3667.120.550.4112.126.495.65174.893.922.9787.751.861.1731.2214.5310.35297.620.680.4814.026.4016.341.490.942.46713.189.01254.840.750.5215.33<</td><td>1.210.50.180.570.5212.710.940.6113.773.252.1850.5821.4433.711.851.330.533.610.530.512.240.840.5512.43.071.9946.542.011.4233.521.841.410.5155.880.520.4912.150.80.5312.052.91.8643.541.951.3732.621.841.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.3331.871.8418.6317.81588.817.016.72219.662.511.8256.185.775.68177.810.320.267.860.3518.4518.08588.067.895.93190.562.312.1362.649.087.56235.630.350.288.520.4312.7511.19355.658.945.61174.672.621.8552.6616.5214.72451.230.430.339.320.526.716.321077.75.68172.92.251.4941.0516.4112.36367.120.550.4112.120.666.495.65174.893.922.9787.751.861.1731.2214.3310.35297.620.651.410.756.495.65174.89</td><td>1.21 0.5 30.18 0.57 0.52 12.71 0.94 0.61 13.77 3.25 2.18 50.58 2 1.44 33.71 1.48 1.44 1.33 0.5 33.61 0.53 0.5 12.24 0.64 0.55 12.4 3.07 1.99 46.54 2.01 1.42 33.52 1.88 1.5 1.41 0.51 35.88 0.52 0.49 12.15 0.8 0.33 11.02 2.75 1.74 41.04 1.91 1.33 31.87 1.8 1.48 1.63 17.81 588.81 7.01 6.72 219.66 2.51 1.82 56.18 5.77 5.68 177.81 0.32 0.26 7.86 0.35 0.29 16.43 18.68 588.66 7.89 5.93 190.56 2.31 1.82 56.18 5.77 5.68 177.81 0.32 0.26 7.86 0.35 0.29 0.43 0.33 0.82 0.43 0.34 0.34 0.34 0.34 0.34 0.34 0.35</td></t<></td></t<>	1.21 0.5 30.18 0.57 0.52 12.71 1.33 0.5 33.61 0.53 0.5 12.24 1.41 0.51 35.88 0.52 0.49 12.15 1.51 0.53 38.54 0.51 0.48 12.36 18.63 17.81 588.81 7.01 6.72 219.66 18.45 18.08 588.06 7.89 5.93 190.56 12.75 11.19 355.65 8.94 5.61 174.67 6.71 6.32 197 7.7 5.68 172.9 6.49 5.65 174.89 3.92 2.97 87.75 6.86 6.03 188.89 3.65 2.89 85.05 7.43 6.59 210.38 3.36 2.79 82.25 7.98 7.13 230.09 3.2 2.75 80.43 8.54 7.69 247.7 3.05 2.67 78.43 8.95 8.1 259.64 2.98 2.63 77.12 9.43 8.59 272.49 2.96 2.63 77.2 4.51 4.78 109.09 3.24 3.39 81.09 4.34 4.68 105.88 4.56 3.7 85.05 2.98 2.93 64.44 6.12 4.33 94.17 1.68 1.77 37.54 5.67 4.69 98.55 1.6 1.56 32.49 3.11 2.67 53.11	1.21 0.5 30.18 0.57 0.52 12.71 0.94 1.33 0.5 33.61 0.53 0.5 12.24 0.84 1.41 0.51 35.88 0.52 0.49 12.15 0.8 1.51 0.53 38.54 0.51 0.48 12.36 0.77 18.63 17.81 588.81 7.01 6.72 219.66 2.51 18.45 18.08 588.06 7.89 5.93 190.56 2.31 12.75 11.19 355.65 8.94 5.61 174.67 2.62 6.71 6.32 197 7.7 5.68 172.9 2.25 6.49 5.65 174.89 3.92 2.97 87.75 1.86 6.86 6.03 188.89 3.65 2.89 85.05 1.49 7.43 6.59 210.38 3.36 2.79 82.25 1.16 7.98 7.13 230.09 3.2 2.75 80.43 0.94 8.54 7.69 247.7 3.05	1.21 0.5 30.18 0.57 0.52 12.71 0.94 0.61 1.33 0.5 33.61 0.53 0.5 12.24 0.84 0.55 1.41 0.51 35.88 0.52 0.49 12.15 0.8 0.53 1.51 0.53 38.54 0.51 0.48 12.36 0.77 0.53 1.51 0.53 38.54 0.51 0.48 12.36 0.77 0.53 18.63 17.81 588.81 7.01 6.72 219.66 2.51 1.82 18.45 18.08 588.06 7.89 5.93 190.56 2.31 2.13 12.75 11.19 355.65 8.94 5.61 174.67 2.62 1.85 6.71 6.32 197 7.7 5.68 172.9 2.25 1.49 6.49 5.65 174.89 3.92 2.97 87.75 1.86 1.17 6.86 6.03 188.89 3.65 2.89 85.05 1.49 0.94 7.43 6.59 210.38 3.36 2.79 82.25 1.16 0.75 7.98 7.13 230.09 3.2 2.75 80.43 0.94 0.62 8.54 7.69 247.7 3.05 2.63 77.2 0.65 0.48 4.51 4.78 109.09 3.24 3.39 81.09 10.45 8 4.34 4.68 105.88 4.56	1.21 0.5 30.18 0.57 0.52 12.71 0.94 0.61 13.77 1.33 0.5 33.61 0.53 0.5 12.24 0.84 0.55 12.4 1.41 0.51 35.88 0.52 0.49 12.15 0.8 0.53 12.05 1.51 0.53 38.54 0.51 0.48 12.36 0.77 0.53 11.92 18.63 17.81 588.81 7.01 6.72 219.66 2.51 1.82 56.18 18.45 18.08 588.06 7.89 5.93 190.56 2.31 2.13 62.64 12.75 11.19 355.65 8.94 5.61 174.67 2.62 1.85 52.56 6.71 6.32 197 7.7 5.68 172.9 2.25 1.49 41.05 6.49 5.65 174.89 3.92 2.97 87.75 1.86 1.17 31.22 6.86 6.03 188.89 3.65 2.89 85.05 1.49 0.94 24.67 7.43 6.59 210.38 3.36 2.79 82.25 1.16 0.75 19.72 7.98 7.13 230.09 3.2 2.75 80.43 0.94 0.62 16.46 8.54 7.69 247.7 3.05 2.67 78.43 0.79 0.53 14.52 8.95 8.1 259.64 2.98 2.63 77.2 0.65 0.48	1.21 0.5 30.18 0.57 0.52 12.71 0.94 0.61 13.77 3.25 1.33 0.5 33.61 0.53 0.5 12.24 0.84 0.55 12.4 3.07 1.41 0.51 35.88 0.52 0.49 12.15 0.8 0.53 12.05 2.9 1.51 0.53 38.54 0.51 0.48 12.36 0.77 0.53 11.92 2.75 1.683 17.81 588.81 7.01 6.72 219.66 2.51 1.82 56.18 5.77 18.45 18.08 588.06 7.89 5.93 190.56 2.31 2.13 62.64 9.08 12.75 11.19 355.65 8.94 5.61 174.67 2.62 1.85 52.56 16.52 6.71 6.32 197 7.7 5.68 172.9 2.25 1.49 41.05 16.41 6.49 5.65 174.89 3.92 2.97 87.75 1.86 1.17 31.22 14.53 6.86 6.03 188.89 3.65 2.89 85.05 1.49 0.94 24.67 13.18 7.43 6.59 210.38 3.36 2.79 82.25 1.16 0.75 19.72 11.83 7.43 6.59 247.7 3.05 2.67 78.43 0.94 0.62 16.46 10.74 8.54 7.69 247.7 3.05 2.63 <	1.210.530.180.570.5212.710.940.6113.773.252.181.330.533.610.530.512.240.840.5512.43.071.991.410.5135.880.520.4912.150.80.5312.052.91.861.510.5338.540.510.4812.360.770.5311.922.751.741.86317.81588.817.016.72219.662.511.8256.185.775.6818.4518.08588.067.895.93190.562.312.1362.649.087.5612.7511.19355.658.945.61174.672.621.8552.5616.5214.726.716.321977.75.68172.92.251.4941.0516.4112.366.495.65174.893.922.9787.751.861.1731.2214.5310.356.866.03188.893.652.8985.051.490.9424.6713.189.017.436.59210.383.362.7982.251.160.7519.7211.837.717.987.13230.093.22.7580.430.940.6216.4610.746.778.547.69247.73.052.6377.20.650.4813.238.545.08	1.21 0.5 30.18 0.57 0.52 12.71 0.94 0.61 13.77 3.25 2.18 50.58 1.33 0.5 33.61 0.53 0.5 12.24 0.84 0.55 12.4 3.07 1.99 46.54 1.41 0.51 35.88 0.52 0.49 12.15 0.8 0.53 12.05 2.9 1.86 43.54 1.51 0.53 38.54 0.51 0.48 12.36 0.77 0.53 11.92 2.75 1.74 41.04 18.63 17.81 588.81 7.01 6.72 219.66 2.51 1.82 56.18 5.77 5.68 177.81 18.43 18.08 588.06 7.89 5.93 190.56 2.31 2.13 62.64 9.08 7.56 235.63 12.75 11.19 355.65 8.94 5.61 174.67 2.62 1.85 52.56 1.652 1.472 451.23 6.71 6.32 197 7.7 5.68 172.9 2.25 1.49 41.	1.210.530.180.570.5212.710.940.6113.773.252.1850.5821.330.533.610.530.512.240.840.5512.43.071.9946.542.011.410.5135.880.520.4912.150.80.5312.052.91.8643.541.951.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.86317.81S88.817.016.72219.662.511.8256.185.775.68177.810.321.84518.08S88.067.895.93190.562.312.1362.649.087.56235.630.351.27511.19355.658.945.61174.672.621.8552.5616.5214.72451.230.436.716.321977.75.68172.92.251.4941.0516.4112.36367.120.556.495.65174.893.922.9787.751.861.1731.2214.5310.35297.620.686.866.03188.893.652.8985.051.490.9424.6713.189.01254.840.757.436.59210.383.362.7982.251.160.7519.721.1837.71215.080.837.98	1.210.530.180.570.521.2.710.940.6113.773.252.1850.5821.441.330.533.610.530.512.240.840.5512.43.071.9946.542.011.421.410.5135.880.520.4912.150.80.5312.052.91.8643.541.951.371.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.331.841.781588.817.016.72219.662.511.8256.185.775.68177.810.320.2618.4518.08588.067.895.93190.562.312.1362.649.087.56235.630.350.2812.7511.19355.658.945.61174.672.621.8552.5616.5214.72451.230.430.336.716.321977.75.68172.92.251.4941.0516.4112.36367.120.550.416.495.65174.893.922.9787.751.861.1731.2214.3310.35297.620.680.486.866.03188.893.652.498.501.490.9424.6713.189.01254.840.750.527.436.5921.0383.362.47 <t< td=""><td>1.210.530.180.570.5212.710.940.6113.775.252.1850.5821.4433.711.330.533.610.530.512.240.840.5512.43.071.9946.542.011.4233.521.410.5135.880.520.4912.150.80.5312.052.91.8643.541.951.3732.621.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.3331.871.6317.81588.817.016.72219.662.511.8256.185.775.68177.810.320.267.8618.4518.08588.067.895.93190.562.312.1362.649.087.56235.630.350.288.5212.7511.19355.658.945.61174.672.621.8552.5616.5214.72451.230.430.339.826.716.321977.75.68172.92.251.4941.0516.4112.3667.120.550.4112.126.495.65174.893.922.9787.751.861.1731.2214.5310.35297.620.680.4814.026.4016.341.490.942.46713.189.01254.840.750.5215.33<</td><td>1.210.50.180.570.5212.710.940.6113.773.252.1850.5821.4433.711.851.330.533.610.530.512.240.840.5512.43.071.9946.542.011.4233.521.841.410.5155.880.520.4912.150.80.5312.052.91.8643.541.951.3732.621.841.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.3331.871.8418.6317.81588.817.016.72219.662.511.8256.185.775.68177.810.320.267.860.3518.4518.08588.067.895.93190.562.312.1362.649.087.56235.630.350.288.520.4312.7511.19355.658.945.61174.672.621.8552.6616.5214.72451.230.430.339.320.526.716.321077.75.68172.92.251.4941.0516.4112.36367.120.550.4112.120.666.495.65174.893.922.9787.751.861.1731.2214.3310.35297.620.651.410.756.495.65174.89</td><td>1.21 0.5 30.18 0.57 0.52 12.71 0.94 0.61 13.77 3.25 2.18 50.58 2 1.44 33.71 1.48 1.44 1.33 0.5 33.61 0.53 0.5 12.24 0.64 0.55 12.4 3.07 1.99 46.54 2.01 1.42 33.52 1.88 1.5 1.41 0.51 35.88 0.52 0.49 12.15 0.8 0.33 11.02 2.75 1.74 41.04 1.91 1.33 31.87 1.8 1.48 1.63 17.81 588.81 7.01 6.72 219.66 2.51 1.82 56.18 5.77 5.68 177.81 0.32 0.26 7.86 0.35 0.29 16.43 18.68 588.66 7.89 5.93 190.56 2.31 1.82 56.18 5.77 5.68 177.81 0.32 0.26 7.86 0.35 0.29 0.43 0.33 0.82 0.43 0.34 0.34 0.34 0.34 0.34 0.34 0.35</td></t<>	1.210.530.180.570.5212.710.940.6113.775.252.1850.5821.4433.711.330.533.610.530.512.240.840.5512.43.071.9946.542.011.4233.521.410.5135.880.520.4912.150.80.5312.052.91.8643.541.951.3732.621.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.3331.871.6317.81588.817.016.72219.662.511.8256.185.775.68177.810.320.267.8618.4518.08588.067.895.93190.562.312.1362.649.087.56235.630.350.288.5212.7511.19355.658.945.61174.672.621.8552.5616.5214.72451.230.430.339.826.716.321977.75.68172.92.251.4941.0516.4112.3667.120.550.4112.126.495.65174.893.922.9787.751.861.1731.2214.5310.35297.620.680.4814.026.4016.341.490.942.46713.189.01254.840.750.5215.33<	1.210.50.180.570.5212.710.940.6113.773.252.1850.5821.4433.711.851.330.533.610.530.512.240.840.5512.43.071.9946.542.011.4233.521.841.410.5155.880.520.4912.150.80.5312.052.91.8643.541.951.3732.621.841.510.5338.540.510.4812.360.770.5311.922.751.7441.041.911.3331.871.8418.6317.81588.817.016.72219.662.511.8256.185.775.68177.810.320.267.860.3518.4518.08588.067.895.93190.562.312.1362.649.087.56235.630.350.288.520.4312.7511.19355.658.945.61174.672.621.8552.6616.5214.72451.230.430.339.320.526.716.321077.75.68172.92.251.4941.0516.4112.36367.120.550.4112.120.666.495.65174.893.922.9787.751.861.1731.2214.3310.35297.620.651.410.756.495.65174.89	1.21 0.5 30.18 0.57 0.52 12.71 0.94 0.61 13.77 3.25 2.18 50.58 2 1.44 33.71 1.48 1.44 1.33 0.5 33.61 0.53 0.5 12.24 0.64 0.55 12.4 3.07 1.99 46.54 2.01 1.42 33.52 1.88 1.5 1.41 0.51 35.88 0.52 0.49 12.15 0.8 0.33 11.02 2.75 1.74 41.04 1.91 1.33 31.87 1.8 1.48 1.63 17.81 588.81 7.01 6.72 219.66 2.51 1.82 56.18 5.77 5.68 177.81 0.32 0.26 7.86 0.35 0.29 16.43 18.68 588.66 7.89 5.93 190.56 2.31 1.82 56.18 5.77 5.68 177.81 0.32 0.26 7.86 0.35 0.29 0.43 0.33 0.82 0.43 0.34 0.34 0.34 0.34 0.34 0.34 0.35

2020-2024	1.79	1.84	38.94	2.23	2.06	40.51	6.86	4.72	89.73	3.43	2.53	47.76	1.82	1.5	29.56	1.8	1.55	36.19
2025-2029	1.91	1.99	42.56	1.99	1.87	36.64	6.04	4.06	78.76	3.27	2.36	43.4	1.9	1.54	30.51	1.78	1.55	35.7
2030-2034	2.05	2.17	46.46	1.75	1.66	33.38	5.49	3.63	72.75	3.03	2.14	39.36	1.92	1.54	30.61	1.73	1.51	34.55
2035-2039	2.17	2.32	49.73	1.67	1.58	32.16	5.41	3.56	72.71	2.84	2.02	36.88	1.88	1.49	29.81	1.67	1.46	33.08
2040-2044	2.34	2.53	53.74	1.59	1.51	31.8	5.31	3.45	73.35	2.68	1.91	34.78	1.85	1.46	29.08	1.6	1.4	31.72
NASH																		
1990-1994	1.06	1.07	29.23	0.66	0.66	17.93	0.63	0.48	11.54	0.44	0.46	10.71	0.12	0.11	2.53	0.21	0.19	4.41
1995-1999	1.06	1.09	29.49	0.93	0.72	18.69	0.78	0.63	14.27	0.69	0.62	14.44	0.14	0.13	2.88	0.26	0.24	5.35
2000-2004	0.76	0.71	18.39	1.23	0.82	20.27	0.8	0.61	13.11	1.2	1.16	27.16	0.18	0.16	3.44	0.32	0.28	6.49
2005-2009	0.42	0.42	10.51	1.16	0.92	21.89	0.7	0.51	10.47	1.22	1.02	22.81	0.23	0.2	4.33	0.38	0.34	7.84
2010-2014	0.43	0.41	9.86	0.7	0.56	12.76	0.6	0.42	8.33	1.17	0.91	19.38	0.29	0.25	5.19	0.43	0.37	8.58
2015-2019	0.5	0.48	11.54	0.62	0.52	11.66	0.49	0.35	6.66	1.15	0.86	17.85	0.33	0.27	5.67	0.47	0.41	9.4
2020-2024	0.57	0.55	13.45	0.53	0.47	10.48	0.42	0.29	5.46	1.1	0.79	16.12	0.36	0.29	6.11	0.51	0.44	10.1
2025-2029	0.62	0.62	15.07	0.48	0.43	9.71	0.35	0.24	4.64	1.05	0.74	14.82	0.38	0.29	6.37	0.53	0.47	10.5
2030-2034	0.67	0.67	16.39	0.44	0.39	9	0.31	0.21	4.16	0.98	0.68	13.59	0.39	0.3	6.46	0.54	0.47	10.54
2035-2039	0.7	0.7	17.12	0.42	0.36	8.64	0.3	0.21	4.06	0.93	0.64	12.76	0.38	0.29	6.36	0.53	0.47	10.29
2040-2044	0.73	0.74	18.04	0.41	0.34	8.45	0.29	0.2	4	0.88	0.61	12.01	0.38	0.28	6.29	0.52	0.46	10.03

Abbreviation: GBD: Global Burden of Disease; HBV: hepatitis B virus; HCV: hepatitis C virus; NASH: non-alcoholic steatohepatitis; DALYs: Disability Adjusted Life Years

		Incider	nce			Mortal	ity		DALYS				
Country	Trend1	Relative change in ASR	Trend2	Relative change in ASR	Trend1	Relative change in ASR (%)	Trend2	Relative change in ASR (%)	Trend1	Relative change in ASR (%)	Trend2	Relative change in ASR (%)	
All causes													
Mainland China	1990-2009	-0.64	2009-2044	0.44	1990-2009	-0.64	2009-2044	0.42	1990-2009	-0.66	2009-2044	0.42	
Taiwan China	1990-2009	0.33	2009-2044	-0.67	1990-2009	-0.91	2009-2044	-0.62	1990-2009	-0.074	2009-2044	-0.98	
Japan	1990-2004	0.46	2004-2044	-0.78	1990-1999	0.24	1999-2044	-0.60	1990-1999	-0.17	1999-2044	-0.99	
Republic of Korea	1990-2004	1.84	2004-2044	-0.39	1990-2004	1.57	2004-2044	-0.73	1990-2004	1.54	2004-2044	-0.64	
United Kingdom	1990-2044	1.69	-		1990-2044	2,50	-		1990-2044	1.08	-		
United States of America	1990-2044	1.15	-		1990-2044	1.00	-		1990-2044	0.91	-		
Alcohol													
Mainland China	1990-2009	-0.62	2009-2044	0.07	1990-2009	-0.63	2009-2044	-0.32	1990-2009	-0.66	2009-2044	0.89	
Taiwan China	1990-2009	0.33	2009-2044	-0.69	1990-2009	0.016	2009-2044	-0.63	1990-2009	-0.06	2009-2044	-0.63	
Japan	1990-2004	0.093	2004-2044	-0.65	1990-1999	0.21	1999-2044	-0.71	1990-1999	0.14	1999-2044	-0.75	
Republic of Korea	1990-2004	2.02	2004-2044	-0.23	1990-2004	1.7	2004-2044	-0.48	1990-2004	1.7	2004-2044	-0.53	
United Kingdom	1990-2044	1.62	-		1990-2019	1.07	2019-2044	-0.01	1990-2019	0.98	2019-2044	0.006	
United States of America	1990-2044	1.04	-		1990-2044	1.34	-		1990-2029	1.4	2029-2044	-0.044	
HBV													
Mainland China	1990-2009	-0.64	2009-2044	0.41	1990-2009	-0.65	2009-2044	0.36	1990-2009	-0.67	2009-2044	0.38	
Taiwan China	1990-2009	0.098	2009-2044	-0.62	1990-2009	-0.15	2009-2044	-0.54	1990-2009	-0.21	2009-2044	-0.55	

Table 2. Trends in disease burden of liver cancer from GBD by etiologies, 1990-2044.

Japan	1990-2044	-0.65	-		1990-2044	-0.74	-		1990-2044	-0.76	-	
Republic of Korea	1990-2004	1.86	2004-2044	-0.48	1990-2004	1.59	2004-2044	-0.65	1990-2004	1.54	2004-2044	-0.69
United Kingdom	1990-2044	1.91	-		1990-2044	0.72	-		1990-2044	1.25	-	
United States of America	1990-2044	1.06	-		1990-2044	0.83	-		1990-2044	0.80	-	
HCV												
Mainland China	1990-2009	-0.63	2009-2044	0.39	1990-2009	-0.63	2009-2044	0.43	1990-2009	-0.66	2009-2044	0.43
Taiwan China	1990-2009	0.75	2009-2044	-0.72	1990-2009	0.75	2009-2044	-0.68	1990-2009	0.22	2009-2044	-0.68
Japan	1990-1999	0.19	1999-2044	-0.57	1990-1999	0.27	1999-2044	-0.66	1990-1999	0.21	1999-2044	-0.69
Republic of Korea	1990-2004	1.71	2004-2044	-0.29	1990-2004	1.42	2004-2044	-0.49	1990-2004	1.48	2004-2044	-0.58
United Kingdom	1990-2044	1.68	-		1990-2019	1.08	2019-2044	0.04	1990-2019	0.97	2019-2044	0.05
United States of America	1990-2044	0.93	-		1990-2044	0.84	-		1990-2044	0.77	-	
NASH												
Mainland China	1990-2009	-0.60	2009-2044	0.74	1990-2009	-0.61	2009-2044	0.76	1990-2009	-0.64	2009-2044	0.72
Taiwan China	1990-2009	0.40	2009-2044	-0.65	1990-2009	0.39	2009-2044	-0.63	1990-2009	0.22	2009-2044	-0.61
Japan	1990-2004	0.27	2004-2044	0.63	1990-1999	0.31	1999-2044	-0.68	1990-1999	0.24	1999-2044	-0.72
Republic of Korea	1990-2004	1.73	2004-2044	-0.27	1990-2004	1.5	2004-2044	-0.47	1990-2004	1.5	2004-2044	-0.56
United Kingdom	1990-2044	2.2	-		1990-2019	1.45	2019-2044	0.03	1990-2019	1.24	2019-2044	0.11
United States of America	1990-2044	1.47	-		1990-2044	1.42	-		1990-2019	1.14	2019-2044	0.06

Abbreviation: GBD: Global Burden of Disease; HBV: hepatitis B virus; HCV: hepatitis C virus; NASH: non-alcoholic steatohepatitis; DALYs: Disability Adjusted Life Years

Figure legends

Figure 1. Trends in liver cancer incidence through 1990 to 2045: observed (solid lines) and predicted rates (dashed lines). Age-standardized to world population per 100,000.

Figure 2. Trends in liver cancer mortality through 1990 to 2045: observed (solid lines)

and predicted rates (dashed lines). Age-standardized to world population per 100,000.

Figure 3. Trends in liver cancer DALYS through 1990 to 2045: observed (solid lines) and predicted rates (dashed lines). Age-standardized to world population per 100,000. DALYS: Disability Adjusted Life Years.











